Research in succession the neuroph...

Research in succession the neurophysiology of alcohol support indicates facilitated dopamine neurotransmission. Johnson and colleagues postulated that topiramate might effectively treat alcohol stay through several mechanisms, including the ability to decrease extracellular release of dopamine in the midbrain and antagonism of glutamate activity at the neuroreceptors.

The authors mannersed a randomized, double-blind, placebo-controlled clinical trial for 12 weeks using topiramate in dosages of up to 300 mg daily. The 150 participants, who were 21 to 65 years of age, met criteria in Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV) for alcohol dependence, had diagnostic scores forward tests of alcohol-use disorders, and reported drinking at least 21 (for participating women) or 35 (for participating men) standard drinks by week in the 90 days before the close attention To be included in the application of mind participants had to have urine toxicology veils that were negative for narcotics, amphetamines, or sedative hypnotics. A protracted list of exclusion criteria included a instant serious medical or psychologic disorder, biochemical abnormality, or coercion into attempting abstinence (eg to avoid imprisonment or maintain employment)

After a comprehensive intake assessment, participants were randomly assigned to treatment with topiramate or placebo. The starting dosage of topiramate, 25 mg daily, was escalated above eight weeks to 300 mg daily. If tolerated, this dosage was maintained for the final four weeks of the reflection All patients received brief behavior compliance-enhancement treatment weekly from pamper practitioners who dispensed medications, and adherence was checked weekly by dint of physicians. Patient compliance with the consideration was assessed by breath alcohol measurements and other indicators of drinking at the weekly visits, plus casts of returned pill packs.

The primary result of self-reported drinking was assessed from the number of drinks by means of day, the percentage of heavy drinking days, and the number of days of abstinence. Patients also reported cravings using a standardized 14-item scale. Objective evidence of drinking was obtained by dint of checking the plasma g-glutamyl transferase concentration.

The 107 men and 43 women enlisted in the study were 42 years of age in succession average, and nearly two thirds were white. The participants reported an average of 1269 to 1473 years of moot points with alcohol use and intakes of 959 to 885 drinks through day during the 90 days before the cogitation The treatment and placebo assign places tos were comparable in all significant honors By the end of the thought both groups showed highly significant reductions athwart baseline in objective and subjective measures of drinking. Patients receiving topiramate were significantly more prosperous than those taking placebo in reducing the number of drinks for day, the number of drinks in succession each drinking day, the percentage of heavy drinking days, and measures of g-glutamyl transferase. They also significantly increased the percentage of abstinent days compared with the placebo group

The significant differences between the assign places tos became apparent at weeks 6 and 8 and increased as the thought progressed. Compared with the placebo collection by the end of the reflection the patients treated with topiramate reported having 288 fewer drinks by day, 3.10 fewer drinks by means of drinking day, 27.6 fewer days of heavy drinking, and 262 more days of abstinence. Changes in the g-glutamyl transferase ratio indicated significantly decreased alcohol intake in the treated cluster These differences between the collections also were apparent in measures of cravings during treatment.

ensues were reported on the assignment of 75 patients to each cluster but only 55 patients in the topiramate assign places to and 48 in the placebo clump completed the study. Dizziness, paresthesia, psychomotor slowing, memory impairment, and weight los were reported more at short intervals by patients taking topiramate, moreover only three patients withdrew from the topiramate form into groups and five from the placebo form into groups because of adverse effects.

The authors bring to an end that topiramate is more effective than placebo as an adjunct treatment of alcohol confidence in a 12-week program. The issue appears to become significant at dosages of 200 mg daily however increases over time as the dosage is increased to a maximum of 300 mg daily; therefore, independent validitys of time and dosage cannot be segregated. They call for further studies of this approach to the treatment of alcohol dependence

Johnson BA, et al. Oral topiramate for treatment of alcohol dependence: a randomised controll trial. Lancet May 17 2003;361:1677-85

COPYRIGHT 2004 American Academy of Family Physicians

COPYRIGHT 2004 Gale Group